VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	11/2/2005 9:54:12 AM
	of 1972

goldman sachs actually sounds positive but.... VICL rptd Q3/05 loss of $0.26, $0.01 worse than our est due to higher expenses. In Q3/05, VICL (1)initiated a P2 trial for a DNA vaccine against HIV (2)finalized a P2 protocol for a therapeutic CMV vaccine (3)granted MRK options to cancer vaccine targets in exchange for sublicenseable rights on HIV vaccines (4)received $3.4MM in grants for a DNA vaccine against avian influenza & for rapid manufacturing, and (5)planned to develop a DNA vaccine against HIV using electroporation delivery technology. We revised our 2005-07 loss est for the better to $0.99, $0.93 & $0.94 from $1.04, $1.20 & $1.13 mainly due to higher share count. VICL has a broad technology platform in DNA gene delivery, solid partners & 2 years cash position. While VICLs rating remains Underperform based on our distribution system, we are encouraged by recent developments on the pipeline. Our coverage view remains Neutral.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next